Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2012 (2012), Article ID 584219, 8 pages
http://dx.doi.org/10.1155/2012/584219
Review Article

Malignant Melanoma and Its Stromal Nonimmune Microecosystem

Department of Dermatopathology, Liège University Hospital, 4000 Liège, Belgium

Received 28 March 2012; Revised 23 May 2012; Accepted 27 May 2012

Academic Editor: Jose R. Conejo-Garcia

Copyright © 2012 Gérald E. Piérard et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Dean, T. Fojo, and S. Bates, “Tumour stem cells and drug resistance,” Nature Reviews Cancer, vol. 5, no. 4, pp. 275–284, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Quatresooz and G. E. Piérard, “Malignant melanoma: from cell kinetics to micrometastases,” American Journal of Clinical Dermatology, vol. 12, no. 2, pp. 77–86, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Ruiter, T. Bogenrieder, D. Elder, and M. Herlyn, “Melanoma-stroma interactions: structural and functional aspects,” The Lancet Oncology, vol. 3, no. 1, pp. 35–43, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Walter-Yohrling, X. Cao, M. Callahan et al., “Identification of genes expressed in malignant cells that promote invasion,” Cancer Research, vol. 63, no. 24, pp. 8939–8947, 2003. View at Google Scholar · View at Scopus
  5. J. Smolle, R. Hofmann-Wellenhof, and R. Fink-Puches, “Melanoma and stroma: an interaction of biological and prognostic importance,” Seminars in Cutaneous Medicine and Surgery, vol. 15, no. 4, pp. 326–335, 1996. View at Google Scholar · View at Scopus
  6. M. Brenner, K. Degitz, R. Besch, and C. Berking, “Differential expression of melanoma-associated growth factors in keratinocytes and fibroblasts by ultraviolet A and ultraviolet B radiation,” British Journal of Dermatology, vol. 153, no. 4, pp. 733–739, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Philips, T. Keller, and C. Holmes, “Reciprocal effects of ascorbate on cancer cell growth and the expression of matrix metalloproteinases and transforming growth factor-β,” Cancer Letters, vol. 256, no. 1, pp. 49–55, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Quatresooz, J. E. Arrese, C. Piérard-Franchimont, and G. E. Piérard, “Immunohistochemical aid at risk stratification of melanocytic neoplasms,” International Journal of Oncology, vol. 24, no. 1, pp. 211–216, 2004. View at Google Scholar · View at Scopus
  9. N. Philips, J. Conte, Y. J. Chen et al., “Beneficial regulation of matrixmetalloproteinases and their inhibitors, fibrillar collagens and transforming growth factor-β by Polypodium leucotomos, directly or in dermal fibroblasts, ultraviolet radiated fibroblasts, and melanoma cells,” Archives of Dermatological Research, vol. 301, no. 7, pp. 487–495, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Quatresooz, M. A. Reginster, and G. E. Piérard, “‘Malignant melanoma microecosystem’: immunohistopathological insights into the stromal cell phenotype (Review),” Experimental and Therapeutic Medicine, vol. 2, no. 3, pp. 379–384, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Franck, V. David, T. R. Aurélie, G. Florent, H. William, and B. Philippe, “Regulation of MMPs during melanoma progression: from genetic to epigenetic,” Anticancer Agents Medicinal Chemistry. In press.
  12. J. G. Goetz, S. Minguet, I. Navarro-Lérida et al., “Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis,” Cell, vol. 146, no. 1, pp. 148–163, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Zigler, T. Kamiya, E. C. Brantley, G. J. Villares, and M. Bar-Eli, “PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis,” Cancer Research, vol. 71, no. 21, pp. 6561–6566, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. F. R. Miller and G. H. Heppner, “Cellular interactions in metastasis,” Cancer and Metastasis Reviews, vol. 9, no. 1, pp. 21–34, 1990. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Willenberg, A. Saalbach, J. C. Simon, and U. Anderegg, “Melanoma cells control HA synthesis in peritumoral fibroblasts via PDGF-AA and PDGF-CC: impact on melanoma cell proliferation,” Journal of Investigative Dermatology, vol. 132, no. 2, pp. 385–393, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. M. M. Mareel, F. M. Van Roy, and M. E. Bracke, “How and when do tumor cells metastasize?” Critical Reviews in Oncogenesis, vol. 4, no. 5, pp. 559–594, 1993. View at Google Scholar · View at Scopus
  17. N. Wernert, “The multiple roles of tumour stroma,” Virchows Archiv, vol. 430, no. 6, pp. 433–443, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. L. A. Liotta and E. C. Kohn, “The microenvironment of the tumour—Host interface,” Nature, vol. 411, no. 6835, pp. 375–379, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. K. P. Dingemans, I. M. Zeeman-Boeschoten, R. F. Keep, and P. K. Das, “Transplantation of colon carcinoma into granulation tissue induces and invasive morphotype,” International Journal of Cancer, vol. 54, no. 6, pp. 1010–1016, 1993. View at Google Scholar · View at Scopus
  20. P. Quatresooz, C. Piérard-Franchimont, P. Paquet, and G. E. Piérard, “Angiogenic fast-growing melanomas and their micrometastases,” European Journal of Dermatology, vol. 20, no. 3, pp. 302–307, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. R. L. Barnhill and C. Lugassy, “Angiotropic malignant melanoma and extravascular migratory metastasis: description of 36 with emphasis on a new mechanism of tumour spread,” Pathology, vol. 36, no. 5, pp. 485–490, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Claessens, G. E. Piérard, C. Piérard-Franchimont, J. E. Arrese, and P. Quatresooz, “Immunohistochemical detection of incipient melanoma micrometastases. Relationship with sentinel lymph node involvement,” Melanoma Research, vol. 15, no. 2, pp. 107–110, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Lugassy and R. L. Barnhill, “Angiotropic melanoma and extravascular migratory metastasis: a review,” Advances in Anatomic Pathology, vol. 14, no. 3, pp. 195–201, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Quatresooz, C. Piérard-Franchimont, and G. E. Piérard, “Diagnostic challenge of desmoplastic melanoma,” Trends in Cancer Research, vol. 3, pp. 27–34, 2007. View at Google Scholar
  25. G. E. Piérard and C. Piérard-Franchimont, “Stochastic relationship between the growth fraction and vascularity of thin malignant melanomas,” European Journal of Cancer, vol. 33, no. 11, pp. 1888–1892, 1997. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Piérard-Franchimont, F. Henry, O. Heymans, and G. E. Piérard, “Vascular retardation in dormant growth-stunted malignant melanomas,” International Journal of Molecular Medicine, vol. 4, no. 4, pp. 403–406, 1999. View at Google Scholar · View at Scopus
  27. B. Basu, S. Biswas, J. Wrigley, B. Sirohi, and P. Corrie, “Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies,” Expert Review of Anticancer Therapy, vol. 9, no. 11, pp. 1583–1598, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Quatresooz, G. E. Piérard, C. Piérard-Franchimont, P. Humbert, and S. Piérard, “Spectral analysis of the microvasculature of primary cutaneous melanoma,” Pathologie Biologie, vol. 60, pp. 149–153, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Izraely, O. Sagi-Assif, A. Klein et al., “The metastatic microenvironment: brain-residing melanoma metastasis and dormant micrometastasis,” International Journal of Cancer. In press. View at Publisher · View at Google Scholar
  30. C. Piérard-Franchimont, J. E. Arrese, A. F. Nikkels, W. Al-Saleh, P. Delvenne, and G. E. Piérard, “Factor XIIIa-positive dendrocytes and proliferative activity of cutaneous cancers,” Virchows Archiv, vol. 429, no. 1, pp. 43–48, 1996. View at Google Scholar · View at Scopus
  31. T. Schatton and M. H. Frank, “Cancer stem cells and human malignant melanoma,” Pigment Cell and Melanoma Research, vol. 21, no. 1, pp. 39–55, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. G. Rappa, O. Fodstad, and A. Lorico, “The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma,” Stem Cells, vol. 26, no. 12, pp. 3008–3017, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Schatton, G. F. Murphy, N. Y. Frank et al., “Identification of cells initiating human melanomas,” Nature, vol. 451, no. 7176, pp. 345–349, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. P. Quatresooz, G. E. Piérard, C. Piérard-Franchimont et al., “Molecular pathways supporting the proliferation staging of malignant melanoma,” International Journal of Molecular Medicine, vol. 24, no. 3, pp. 295–301, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. G. E. Piérard, “Cell proliferation in malignant melanoma: relationship with neoplastic progression,” ISRN Dermatology, vol. 2012, Article ID 828146, 12 pages, 2012. View at Publisher · View at Google Scholar
  36. M. A. Reginster, C. Piérard-Franchimont, G. E. Piérard, and P. Quatresooz, “Molecular dermatopathology in malignant melanoma,” Dermatology Research and Practice, vol. 2012, Article ID 684032, 6 pages, 2012. View at Publisher · View at Google Scholar
  37. S. F. Cramer, “Stem cells for epidermal melanocytes-a challenge for students of dermatopathology,” American Journal of Dermatopathology, vol. 31, no. 4, pp. 331–341, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. D. Fang, T. K. Nguyen, K. Leishear et al., “A tumorigenic subpopulation with stem cell properties in melanomas,” Cancer Research, vol. 65, no. 20, pp. 9328–9337, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. J. M. Grichnik, J. A. Burch, R. D. Schulteis et al., “Melanoma, a tumor based on a mutant stem cell?” Journal of Investigative Dermatology, vol. 126, no. 1, pp. 142–153, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. K. Buac and W. J. Pavan, “Stem cells of the melanocyte lineage,” Cancer Biomarkers, vol. 3, no. 4-5, pp. 203–209, 2007. View at Google Scholar · View at Scopus
  41. W. M. Klein, B. P. Wu, S. Zhao, H. Wu, A. J. P. Klein-Szanto, and S. R. Tahan, “Increased expression of stem cell markers in malignant melanoma,” Modern Pathology, vol. 20, no. 1, pp. 102–107, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. M. B. Nicholl, D. Elashoff, H. Takeuchi, D. L. Morton, and D. S. B. Hoon, “Molecular upstaging based on paraffin-embedded sentinel lymph nodes: ten-year follow-up confirms prognostic utility in melanoma patients,” Annals of Surgery, vol. 253, no. 1, pp. 116–122, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. P. Quatresooz, C. Piérard-Franchimont, F. Noël, and G. E. Piérard, “Thigmotropism of malignant melanoma cells,” Dermatology Research and Practice, vol. 2012, Article ID 362784, 6 pages, 2012. View at Publisher · View at Google Scholar
  44. K. Maeda, J. I. Hamada, Y. Takahashi et al., “Altered expressions of HOX genes in human cutaneous malignant melanoma,” International Journal of Cancer, vol. 114, no. 3, pp. 436–441, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. A. I. Riker, S. A. Enkemann, O. Fodstad et al., “The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis,” BMC Medical Genomics, vol. 28, article 13, 2008. View at Google Scholar
  46. M. Yang, Q. F. Li, and F. Zhang, “HOX genes in the skin,” Chinese Medical Journal, vol. 123, no. 18, pp. 2607–2612, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. G. E. Piérard, C. Piérard-Franchimont, and P. Delvenne, “HOX gene expressions in skin melanoma,” Oncology Reports. In press.
  48. C. C. Lynch and L. M. Matrisian, “Matrix metalloproteinases in tumor-host cell communication,” Differentiation, vol. 70, no. 9-10, pp. 561–573, 2002. View at Publisher · View at Google Scholar · View at Scopus
  49. R. Ádány and H. Bárdos, “Factor XIII subunit A as an intracellular transglutaminase,” Cellular and Molecular Life Sciences, vol. 60, no. 6, pp. 1049–1060, 2003. View at Google Scholar · View at Scopus
  50. J. Arrese Estrada and G. E. Piérard, “Factor-XIIIa-positive dendrocytes and the dermal microvascular unit,” Dermatologica, vol. 180, no. 1, pp. 51–53, 1990. View at Google Scholar · View at Scopus
  51. P. Quatresooz, P. Paquet, T. Hermanns-Lê, and G. E. Piérard, “Molecular mapping of factor XIIIa-enriched dendrocytes in the skin (review),” International Journal of Molecular Medicine, vol. 22, no. 4, pp. 403–409, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. P. Quatresooz and G. E. Piérard, “Immunohistochemical clues at aging of the skin microvascular unit,” Journal of Cutaneous Pathology, vol. 36, no. 1, pp. 39–43, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. D. R. Fullen and J. T. Headington, “Factor XIIIa-positive dermal dendritic cells and HLA-DR expression in radial versus vertical growth-phase melanomas,” Journal of Cutaneous Pathology, vol. 25, no. 10, pp. 553–558, 1998. View at Google Scholar · View at Scopus
  54. K. J. Denton, D. W. K. Cotton, A. Wright, and P. Hird, “Factor XIIIa in nodular malignant melanoma and Spitz naevi,” British Journal of Dermatology, vol. 123, no. 6, pp. 783–786, 1990. View at Publisher · View at Google Scholar · View at Scopus
  55. M. E. Polak, P. Johnson, S. Di Palma et al., “Presence and maturity of dendritic cells in melanoma lymph node metastases,” Journal of Pathology, vol. 207, no. 1, pp. 83–90, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. C. Wessel, C. C. Westhoff, K. Nowak, I. Moll, and P. J. Barth, “CD34+ fibrocytes in melanocytic nevi and malignant melanomas of the skin,” Virchows Archiv, vol. 453, no. 5, pp. 485–489, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. C. Lugassy, B. P. Eyden, L. Christensen, and J. P. Escande, “Angio-tumoral complex in human malignant melanoma characterised by free laminin: ultrastructural and immunohistochemical observations,” Journal of Submicroscopic Cytology and Pathology, vol. 29, no. 1, pp. 19–28, 1997. View at Google Scholar · View at Scopus
  58. G. Schaumburg-Lever, I. Lever, B. Fehrenbacher et al., “Melanocytes in nevi and melanomas synthesize basement membrane and basement membrane-like material. An immunohistochemical and electron microscopic study including immunoelectron microscopy,” Journal of Cutaneous Pathology, vol. 27, no. 2, pp. 67–75, 2000. View at Publisher · View at Google Scholar · View at Scopus
  59. C. M. Van Duinen, G. J. Fleuren, and J. A. Bruijn, “The extracellular matrix in pigmented skin lesions: an immunohistochemical study,” Histopathology, vol. 24, no. 1, pp. 33–40, 1994. View at Google Scholar · View at Scopus
  60. C. Lugassy, G. R. Dickersin, L. Christensen et al., “Ultrastructural and immunphistochemical studies of the periendothelial matrix in human melanoma: evidence for an amorphous matrix containing laminin,” Journal of Cutaneous Pathology, vol. 26, no. 2, pp. 78–83, 1999. View at Google Scholar · View at Scopus
  61. C. Lugassy, A. Shahsafaei, P. Bonitz, K. J. Busam, and R. L. Barnhill, “Tumor microvessels in melanoma express the beta-2 chain of laminin. Implications for melanoma metastasis,” Journal of Cutaneous Pathology, vol. 26, no. 5, pp. 222–226, 1999. View at Publisher · View at Google Scholar · View at Scopus
  62. P. Quatresooz and G. E. Piérard, “Immunohistochemical investigation of α1 (IV) and α5 (IV) collagen chains in a broad spectrum of melanocytic tumours,” Melanoma Research, vol. 15, no. 3, pp. 161–168, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. T. N. Wight, “Versican: a versatile extracellular matrix proteoglycan in cell biology,” Current Opinion in Cell Biology, vol. 14, no. 5, pp. 617–623, 2002. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Touab, J. Villena, C. Barranco, M. Arumí-Uría, and A. Bassols, “Versican is differentially expressed in human melanoma and may play a role in tumor development,” American Journal of Pathology, vol. 160, no. 2, pp. 549–557, 2002. View at Google Scholar · View at Scopus
  65. M. Serra, L. Miquel, C. Domenzain et al., “V3 versican isoform expression alters the phenotype of melanoma cells and their tumorigenic potential,” International Journal of Cancer, vol. 114, no. 6, pp. 879–886, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. L. Miquel-Serra, M. Serra, D. Hernández et al., “V3 versican isoform expression has a dual role in human melanoma tumor growth and metastasis,” Laboratory Investigation, vol. 86, no. 9, pp. 889–901, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. M. J. Docampo, R. M. Rabanal, L. Miquel-Serra, D. Hernández, C. Domenzain, and A. Bassols, “Altered expression of versican and hyaluronan in melanocytic tumors of dogs,” American Journal of Veterinary Research, vol. 68, no. 12, pp. 1376–1385, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. T. Gambichler, A. Kreuter, S. Grothe, P. Altmeyer, N. H. Brockmeyer, and S. Rotterdam, “Versican overexpression in cutaneous malignant melanoma,” European Journal of Medical Research, vol. 13, no. 11, pp. 500–504, 2008. View at Google Scholar · View at Scopus
  69. L. Miquel-Serra, D. Hernández, M. J. Docampo, and A. Bassols, “Differential expression of endoglin in human melanoma cells expressing the V3 isoform of versican by microarray analysis,” Molecular Medicine Reports, vol. 3, no. 6, pp. 1035–1039, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. D. Hernández, L. Miquel-Serra, M. J. Docampo, A. Marco-Ramell, and A. Bassols, “Role of versican V0/V1 and CD44 in the regulation of human melanoma cell behavior,” International Journal of Molecular Medicine, vol. 27, no. 2, pp. 269–275, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. D. Hernández, L. Miquel-Serra, M. J. Docampo et al., “V3 versican isoform alters the behavior of human melanoma cells by interfering with CD44/ErbB-dependent signaling,” The Journal of Biological Chemistry, vol. 286, no. 2, pp. 1475–1485, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. G. S. Bogatkevich, E. Tourkina, R. M. Silver, and A. Ludwicka-Bradley, “Thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via the proteolytically activated receptor-1 and a protein kinase C-dependent pathway,” The Journal of Biological Chemistry, vol. 276, no. 48, pp. 45184–45192, 2001. View at Publisher · View at Google Scholar · View at Scopus
  73. G. Serini, M. L. Bochaton-Piallat, P. Ropraz et al., “The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-β1,” Journal of Cell Biology, vol. 142, no. 3, pp. 873–881, 1998. View at Publisher · View at Google Scholar · View at Scopus
  74. B. Hinz and G. Gabbiani, “Mechanisms of force generation and transmission by myofibroblasts,” Current Opinion in Biotechnology, vol. 14, no. 5, pp. 538–546, 2003. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Okamoto-Inoue, J. Nakayama, Y. Hori, and S. Taniguchi, “Human malignant melanoma cells release a factor that inhibits the expression of smooth muscle α-actin,” Journal of Dermatological Science, vol. 23, no. 3, pp. 170–177, 2000. View at Publisher · View at Google Scholar · View at Scopus
  76. S. Seité, D. Moyal, S. Richard et al., “Effects of repeated suberythemal doses of UVA in human skin,” European Journal of Dermatology, vol. 7, no. 3, pp. 204–209, 1997. View at Google Scholar · View at Scopus
  77. S. Seité, H. Zucchi, D. Septier, S. Igondjo-Tchen, K. Senni, and G. Godeau, “Elastin changes during chronological and photo-ageing: the important role of lysozyme,” Journal of the European Academy of Dermatology and Venereology, vol. 20, no. 8, pp. 980–987, 2006. View at Publisher · View at Google Scholar · View at Scopus
  78. C. Piérard-Franchimont, I. Uhoda, D. Saint-Léger, and G. E. Piérard, “Androgenic alopecia and stress-induced premature senescence by cumulative ultraviolet light exposure,” Exogenous Dermatology, vol. 1, no. 4, pp. 203–206, 2002. View at Publisher · View at Google Scholar · View at Scopus
  79. S. E. Williams, T. I. Brown, A. Roghanian, and J. M. Sallenave, “SLPI and elafin: one glove, many fingers,” Clinical Science, vol. 110, no. 1, pp. 21–35, 2006. View at Publisher · View at Google Scholar · View at Scopus
  80. F. Nozawa, M. Hirota, A. Okabe et al., “Elastase activity enhances the adhesion of neutrophil and cancer cells to vascular endothelial cells,” Journal of Surgical Research, vol. 94, no. 2, pp. 153–158, 2000. View at Publisher · View at Google Scholar · View at Scopus
  81. K. S. Yu, Y. Lee, C. M. Kim et al., “The protease inhibitor, elafin, induces p53-dependent apoptosis in human melanoma cells,” International Journal of Cancer, vol. 127, no. 6, pp. 1308–1320, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. H. F. Dvorak, “Tumors: wounds that do not heal: similarities between tumor stroma generation and wound healing,” The New England Journal of Medicine, vol. 315, no. 26, pp. 1650–1659, 1986. View at Google Scholar · View at Scopus
  83. J. Marcoval, A. Moreno, J. Graells et al., “Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase,” Journal of Cutaneous Pathology, vol. 24, no. 4, pp. 212–218, 1997. View at Google Scholar · View at Scopus
  84. K. A. Zaki, B. Basu, and P. Corrie, “The role of angiogenesis inhibitors in the management of melanoma,” Current Topics in Medicinal Chemistry, vol. 12, no. 1, pp. 32–49, 2012. View at Publisher · View at Google Scholar · View at Scopus
  85. D. C. Bennett, “Ultraviolet wavebands and melanoma initiation,” Pigment Cell and Melanoma Research, vol. 21, no. 5, pp. 520–524, 2008. View at Publisher · View at Google Scholar · View at Scopus
  86. S. R. Alonso, P. Ortiz, M. Pollán et al., “Progression in cutaneous malignant melanoma is associated with distinct expression profiles. A tissue microarray-based study,” American Journal of Pathology, vol. 164, no. 1, pp. 193–203, 2004. View at Google Scholar · View at Scopus
  87. L. A. Fecher, S. D. Cummings, M. J. Keefe, and R. M. Alani, “Toward a molecular classification of melanoma,” Journal of Clinical Oncology, vol. 25, no. 12, pp. 1606–1620, 2007. View at Publisher · View at Google Scholar · View at Scopus
  88. J. A. Plaza, D. Suster, and D. Perez-Montiel, “Expression of immunohistochemical markers in primary and metastatic malignant melanoma: a comparative study in 70 patients using a tissue microarray technique,” Applied Immunohistochemistry and Molecular Morphology, vol. 15, no. 4, pp. 421–425, 2007. View at Publisher · View at Google Scholar · View at Scopus
  89. S. J. Ohsie, G. P. Sarantopoulos, A. J. Cochran, and S. W. Binder, “Immunohistochemical characteristics of melanoma,” Journal of Cutaneous Pathology, vol. 35, no. 5, pp. 433–444, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. P. Quatresooz, C. Piérard-Franchimont, and G. E. Piérard, “Highlighting the immunohistochemical profile of melanocytomas,” Oncology Reports, vol. 19, no. 6, pp. 1367–1372, 2008. View at Google Scholar · View at Scopus
  91. S. Hamza, “Prognostic parameters of malignant melanoma,” Diagnostic Histopathology, vol. 16, no. 7, pp. 330–336, 2010. View at Publisher · View at Google Scholar · View at Scopus
  92. V. Gray-Schopfer, C. Wellbrock, and R. Marais, “Melanoma biology and new targeted therapy,” Nature, vol. 445, no. 7130, pp. 851–857, 2007. View at Publisher · View at Google Scholar · View at Scopus
  93. G. E. Piérard, P. Quatresooz, A. Rorive, and C. Piérard-Franchimont, “Malignant melanoma: conceptual and therapeutic innovations based on translational research,” Revue Medicale de Liege, vol. 63, no. 10, pp. 579–584, 2008. View at Google Scholar · View at Scopus
  94. C. Piérard-Franchimont and G. E. Piérard, “Metastatic melanoma: some hope from ipilipumab and vemurafenib,” Revue Médicale de Liège, vol. 67, pp. 64–68, 2012. View at Google Scholar
  95. A. Joannou-Coetzee, N. Villena, B. W. E. M. Powell, and M. G. Cook, “Assessment of proliferation markers in metastatic melanoma in sentinel lymph nodes,” Journal of Clinical Pathology, vol. 64, no. 12, pp. 1108–1111, 2011. View at Publisher · View at Google Scholar · View at Scopus
  96. K. Dutton-Regester, D. Irwin, P. Hunt et al., “A high throughput panel of identifying clinically-relevant mutation profiles in melanoma,” Molecular Cancer Therapy, vol. 11, pp. 888–897, 2012. View at Google Scholar
  97. J. G. Monzon and J. Dancey, “Targeted agents for the treatment of metastatic melanoma,” OncoTargets and Therapy, vol. 5, pp. 31–46, 2012. View at Publisher · View at Google Scholar · View at Scopus
  98. Y.-Y. Hu, M.-H. Zheng, R. Zhang, Y.-M. Liang, and H. Han, “Notch signaling pathway and cancer metastasis,” Advances in Experimental Medicine and Biology, vol. 727, pp. 186–198, 2012. View at Publisher · View at Google Scholar · View at Scopus
  99. M. Gardizi, C. Kurschat, A. Riese et al., “A decreased ratio between serum levels of the antagonistic angiopoietins 1 and 2 indicates tumour progression of malignant melanoma,” Archives of Dermatological Research. In press. View at Publisher · View at Google Scholar · View at Scopus
  100. O. De Wever and M. Mareel, “Role of tissue stroma in cancer cell invasion,” Journal of Pathology, vol. 200, no. 4, pp. 429–447, 2003. View at Publisher · View at Google Scholar · View at Scopus